SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



          Date of Report (Date of earliest event reported) May 25, 2006



                         Progenics Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)



              Delaware                  000-23143            13-3379479
    (State or other jurisdiction        (Commission         (IRS Employer
         of incorporation)              File Number)      Identification No.)


             777 Old Saw Mill River Road, Tarrytown, New York 10591
               (Address of principal executive offices) (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800


         (Former name or former address, if changed since last report.)






Section 7.01 - Regulation FD Disclosure

     Progenics   Pharmaceuticals,   Inc.  (Nasdaq:  PGNX)  today  announced  the
expansion of its  collaboration  with Seattle Genetics,  Inc. (Nasdaq:  SGEN) to
include  activities  intended to accelerate the manufacturing and development of
Progenics'  prostate-specific  membrane antigen (PSMA)  antibody-drug  conjugate
(ADC).  A copy of the press  release is attached  hereto as Exhibit 99.1 and the
information  contained  therein is incorporated by reference into this Item 7.01
of this Current Report on Form 8-K.

     The information  furnished pursuant to Item 7.01 in this Form 8-K shall not
be deemed  to be  "filed"  for the  purposes  of  Section  18 of the  Securities
Exchange Act of 1934 or otherwise  subject to the  liabilities  of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the  Securities  Exchange Act of 1934. We undertake no
duty or  obligation  to  publicly  update or revise  the  information  furnished
pursuant to Item 7.01 in this Form 8-K.

Section 9.01 - Financial Statements and Exhibits

(c)      Exhibits

Exhibit Number    Description
- --------------    -----------
99.1              Press release dated May 25, 2006




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                               PROGENICS PHARMACEUTICALS, INC.


                               By:  /s/ MARK R. BAKER
                               ------------------------------------------------
                                        Mark R. Baker
                                        Senior Vice President & General Counsel

Date: May 25, 2006